Sign In
Buy BIO
$301.70
-0.200 (-0.0662%)
At Close: Jul 21, 2026
Medical Device Stocks to Watch for Earnings on Jul 28
04:05pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, TMO and BIO will likely fare this time.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
01:49pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Bio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus on laboratory workflow productivity, quality control, and new opportunities in molecular diagnostic
Tesla, Danaher And Some Other Big Gainers From Yesterday
09:40am, Friday, 22'nd Jul 2022 Benzinga
U.S. stocks closed higher on Thursday, with the Nasdaq Composite jumping around 1.4%. Here is the list of some big stocks recording gains in the previous session.
Tabula Rasa HealthCare, Inc. (NASDAQ
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
09:04am, Friday, 22'nd Jul 2022 Benzinga
Gainers
Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up peri
Why Is Super Micro Computer Higher By More Than 13%? 42 Stocks Moving In Thursday's Mid-Day Session
04:33pm, Thursday, 21'st Jul 2022 Benzinga
Gainers
Virax Biolabs Group Limited (NASDAQ: VRAX) shares jumped 364.3% to $23.22. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days endin
Bio-Rad to Report Second Quarter 2022 Financial Results on Thursday, July 28, 2022
04:15pm, Monday, 18'th Jul 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
04:38pm, Friday, 17'th Jun 2022 Zacks Investment Research
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
01:55pm, Friday, 17'th Jun 2022
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
01:47pm, Thursday, 16'th Jun 2022 Zacks Investment Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at the Animal Health segment.
Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
03:03pm, Monday, 06'th Jun 2022 Zacks Investment Research
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.
Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
12:47pm, Monday, 06'th Jun 2022
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.
Why Is NuVasive (NUVA) Up 6.3% Since Last Earnings Report?
03:31pm, Friday, 03'rd Jun 2022 Zacks Investment Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cooper Companies (COO) Q2 Earnings Miss Estimates, Revenues Top
02:26pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal second-quarter earnings reflect solid segmental performance.
Medtronic's (MDT) Q4 Earnings and Revenues Lag Estimates
02:21pm, Thursday, 26'th May 2022 Zacks Investment Research
On a positive note, Medtronic (MDT) registers organic growth in the Cardiovascular and Neuroscience segments.
Change Healthcare (CHNG) Q4 Earnings Miss Estimates, Revenues Top
02:05pm, Thursday, 26'th May 2022 Zacks Investment Research
Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.
